Peptide News Digest

#Rrmm

1 story

Regulatory · View digest

Oncopeptides Plans EMA Type II Variation to Expand Pepaxti (Melflufen) Peptide-Drug Conjugate Label to Third-Line Multiple Myeloma

Oncopeptides announced on Monday, May 11, 2026 that it intends to submit a Type II variation application to the European Medicines Agency to extend the Pepaxti (melflufen) label to third-line multiple myeloma, with first regulatory feedback expected before the end of 2026 and a European Commission decision in the first half of 2027. Pepaxti, a peptide-drug conjugate given with dexamethasone, is authorized in the EU for adults who have had at least three prior lines of therapy and whose disease is refractory to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. The company said a third-line label would double Pepaxti's addressable patient population in Europe. The drug is not available in the U.S.: the FDA withdrew its approval, under the name Pepaxto, on February 23, 2024.